MicroRNA 4650-2 (MIR4650-2)

MicroRNA 4650-2 is a predicted or annotated human microRNA, designated as hsa-mir-4650-2 in genomic databases such as miRBase[4]. MicroRNAs are a class of small, non-coding RNAs that regulate gene expression post-transcriptionally by base-pairing with target mRNAs, typically resulting in lowered translation and/or increased mRNA degradation[2][3][5]. The mechanisms of microRNA action involve association with Argonaute proteins within the RISC complex. There is no readily available disease association, functional assay, or therapeutic targeting data for MIR4650-2 specifically in the literature, indicating it is not a recognized therapeutic target at this time. Based on current evidence, listing it as a drug target or validated biomarker is premature. Its inclusion in curated lists may be due to automated genome annotation and not due to established biological or pharmacological function. MicroRNAs (miRNAs) are regulatory molecules with significant roles in gene expression modulation but do not correspond to classic drug targets like receptors, enzymes, transporters, or ion channels[2][3]. hsa-mir-4650-2 appears in miRBase[4], documenting experimental or computational identification, but there are no publications linking it directly to disease states, drug involvement, or validated clinical biomarker status. The apparent repetition of the name among aliases is due to various database nomenclature conventions (hsa = human, mir = microRNA).

Other names

hsa-mir-4650-2MIR4650-2microRNA 4650-2

Not a direct target of drugs; as with other microRNAs, regulates gene expression via RNA-induced silencing complex (RISC) binding to target mRNAs, leading to translational repression or mRNA degradation